Evidence map›Paper›PMID 39956649›Full record

Trial reportEuropean journal of heart failure2025

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial.

Clara I Saldarriaga, Faiez Zannad, Ciaran J McMullan, Aiwen Xing, Davis Gates, Kevin J Anstrom, Marc P Bonaca, Stefano Corda, Justin A Ezekowitz, Carolyn S P Lam and 12 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05093933 (A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05093933 phase3completednot on this map

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2021 to 2025Enrolled6,106ConditionsChronic Heart Failure With Reduced Ejection FractionArmsVericiguat, Placebo
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Clara I SaldarriagaCardio VID Clinic, Medellin, Colombia.
Faiez ZannadCVCT and Université de Lorraine, Nancy, France.
Ciaran J McMullanMerck & Co., Inc., Rahway, NJ, USA.
Aiwen XingMerck & Co., Inc., Rahway, NJ, USA.
Davis GatesMerck & Co., Inc., Rahway, NJ, USA.
Kevin J AnstromUniversity of North Carolina, Chapel Hill, NC, USA.
Marc P BonacaColorado Prevention Center Clinical Research, Department of Medicine, University of Colorado, Aurora, CO, USA.
Stefano CordaBayer AG, Basel, Switzerland.
Justin A EzekowitzCanadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
Carolyn S P LamNational Heart Centre Singapore and Duke-National University, Singapore, Singapore.
Eldrin F LewisStanford University School of Medicine, Stanford, CA, USA.
JoAnn LindenfeldVanderbilt University Medical Center, Nashville, TN, USA.
Robert J MentzDuke Clinical Research Institute, Durham, NC, USA.
Christopher O'ConnorInova Heart and Vascular Institute, Falls Church, VA, USA.
Mahesh PatelMerck & Co., Inc., Rahway, NJ, USA.
Piotr PonikowskiWroclaw Medical University, Wroclaw, Poland.
Yogesh N V ReddyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Giuseppe M C RosanoDepartment of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome, Rome, Italy.
Michele SenniUniversity of Milano-Bicocca, Milan, Italy.
James UdelsonTufts Medical Center, Boston, MA, USA.
Adriaan A VoorsUniversity of Groningen, Groningen, The Netherlands.
Javed ButlerDepartment of Medicine, University of Mississippi, Jackson, MS, USA.

Funding

Bayer AG, Wuppertal, GermanyMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
6 · The paper itself

Abstract

aimsTo describe the baseline characteristics of the participants in the VICTOR (Vericiguat Global Study in Patients with Chronic Heart Failure; NCT05093933) trial and compare them to recent trials in patients with heart failure and reduced ejection fraction (HFrEF). METHODS AND

resultsBaseline characteristics were evaluated in 6105 patients randomized to vericiguat or placebo. The mean age of the participants was 67 ± 11 years, 23.6% were women, 64.4% were White, and 10.7% were self-identified Black. Overall, 29.1% of participants were enrolled in Latin and South America, 27.8% and 18.5% in Eastern and Western Europe, 14.0% in Asia-Pacific and 10.6% in North America. The mean left ventricular ejection fraction was 30 ± 7% and 79% had New York Heart Association class II symptoms. Mean estimated glomerular filtration rate was 70.9 ± 24.0 ml/min/1.73 m

conclusionThe VICTOR trial enrolled the most optimally treated population in a phase III heart failure trial. These features will facilitate assessment of the benefit of vericiguat and elucidate the outcomes of patients on up-to-date medical therapy.

Indexed as

AminobutyratesHeart FailureStroke VolumeVentricular Function, LeftAgedDouble-Blind MethodFemaleHeterocyclic Compounds, 2-RingHumansMaleMiddle AgedMineralocorticoid Receptor AntagonistsPyrimidinesSodium-Glucose Transporter 2 InhibitorsTreatment OutcomeAminobutyratesHeterocyclic Compounds, 2-RingMineralocorticoid Receptor AntagonistsPyrimidinesSodium-Glucose Transporter 2 InhibitorsvericiguatClinical characteristicsHeart failureTreatmentVericiguat

Identifiers

PMID39956649
PMCPMC12482839

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.